Menu
  • Join
  • Login
  • Contact
 

Search abstracts / presentations


New drug targeting and monitoring of bendamustine treatment in patients with chronic lymphocytic leukemia (cll)

  • In: Hospital Pharmacy Section Posters
  • At: New Orleans (USA) (2004)
  • Type: Poster
  • Poster code: HPS-P001
  • By: KOSTOVSKI, Aleksandar (Faculty of Pharmacy, Sofia, Pharmacology and Toxicology, Sofia, Bulgaria)
  • Co-author(s): Konstantinov (Faculty of Pharmacy, Sofia, SOFIA, Bulgaria)
    Alaikov (University Hospital St. Anna, Bulgaria)
    Karaivanova (Faculty of Pharmacy, Sofia, SOFIA, Bulgaria)
  • Abstract:

    Summary

    CLL is characterized by a progressive accumulation of functionally incompetent long-lived CD5+ B-lymphocytes which are monoclonal in origin. Bendamustine is a benzimidazole derivative with two alkylating groups. Fludarabine is a fluorinated adenine derivative belongs to the group of antimetabolites. Erucylphospho-N, N,..

  • The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 September 2025

FIP Congresses